key: cord-0989532-kvr2blz1 authors: Hsieh, Cheng-Fang; Liu, Ching-Kuan; Fang, Tzu-Jung; Yu, Yau-Hua; Lai, Chiou-Lian; Kuo, Hsu-Ko title: Previous Hepatitis A Virus Infection Is Related to Slower Psychomotor Speed in Elderly Adults date: 2009-06-26 journal: J Gerontol A Biol Sci Med Sci DOI: 10.1093/gerona/glp081 sha: 5f250fbe422953adbc5cf58f43f99858d363b259 doc_id: 989532 cord_uid: kvr2blz1 BACKGROUND: Patients with chronic viral hepatitis are at a higher risk for cognitive dysfunction. Little is known about the association between hepatitis A virus (HAV) infection and cognitive function. METHODS: From the National Health and Nutrition Examination Survey, 1999–2002, we selected study participants (≥60 years, n = 1,529) without hepatitis B, C, or D virus infection; without previous hepatitis A vaccination; and without abnormal liver function. HAV-seropositive participants represented people with previous HAV infection. Psychomotor speed and executive functioning domain of cognitive function were measured by the Digit Symbol Substitution Test (DSST). RESULTS: HAV-seropositive participants had lower DSST scores than HAV-seronegative participants (weighted mean, 44.4 vs 53.9, p < .001). We designated HAV-seronegative participants as the reference group. Univariate analysis demonstrated that the weighted β coefficient of DSST score was −9.55 (95% confidence interval [CI] −9.57 to −9.54, p < .001) for the HAV-seropositive participants. In a multivariable model, the weighted adjusted β coefficient of DSST score was −2.48 (95% CI −2.49 to −2.46, p < .001) for the HAV-seropositive participants. CONCLUSION: HAV seropositivity is associated with slower psychomotor speed among the U.S. community-dwelling elders. cluster sampling design to obtain a representative sample of the noninstitutionalized civilian U.S. population. Detailed survey operations manuals, consent documents, and brochures of the NHANES 1999 -2002 are available in the NHANES Web site ( 19 , 20 ) . Psychomotor speed and executive functioning domain of cognitive function were assessed in the NHANES participants aged 60 years and older using the Digit Symbol Substitution Test (DSST). Among the 2,975 participants who completed the DSST, we excluded 223 people with hepatitis B, C, or D virus infection; 175 people with previous HAV vaccination; and 880 people with missing study parameters. We also excluded 168 persons who had abnormal liver function tests so that HAV-seropositive participants represented people with previous HAV infection. Those with nonmissing values tended to perform better in the DSST (43.2 vs 38.3 points), be younger (71.4 vs 72.7 years), be non-Hispanic white (64.3% vs 57.7%), have higher education level, and have higher annual family income. Thus, the analytic sample consisted of 1,529 participants with complete information on the DSST, HAV marker, and covariates required for analyses. The DSST, a component of the Wechsler Adult Intelligence Test ( 21 ) and a test of visuospatial and motor speed of processing, has a considerable executive function component and is frequently used as a sensitive measure of frontal lobe executive functions ( 22 , 23 ) . Participants were asked to copy symbols that were paired with numbers within 2 minutes. Following the standard scoring method, one point is given for each correctly drawn symbol. The maximum score is 133. Other cognitive domains such as short-term memory, long-term memory, and verbal ability were not assessed in the NHANES 1999 -2002. Hepatitis A antibody was measured using enzyme immunoassay, and the results were expressed as " positive " or " negative. " The assay used in this measurement cannot differentiate between natural infection and vaccination. Therefore, seropositivity for hepatitis A antibody refl ects either natural or vaccine-induced immunity. Age, gender, race, educational level, and annual family income were obtained from self-report. Diabetes mellitus was defi ned by a self-report doctor ' s diagnosis, the presence of a fasting glucose level of 126 mg/dL or greater, the presence of a random glucose level of 200 mg/dL or greater, or the use of diabetic medications (insulin or oral antidiabetic agents). The presence of hypertension was defi ned by a self-report of the doctor ' s diagnosis, the use of antihyper-tensive medications, or an average blood pressure of 140/90 mmHg or higher. Other comorbidities including stroke, myocardial infarction, coronary heart disease, congestive heart failure, angina, asthma, chronic bronchitis, and emphysema were ascertained by self-report. Cardiovascular disease was defi ned if participants had stroke, myocardial infarction, angina, coronary heart disease, or congestive heart failure, whereas lung disease was defi ned if participants had asthma, chronic bronchitis, or emphysema. Kidney disease was defi ned by a history of kidney problem or hemodialysis, an estimated creatinine clearance of less than 60 mL/min (using the Modifi cation of Diet in Renal Disease formula), or the presence of microalbuminuria (spot urine microalbumin to creatinine ratio ≥ 30 mg/g). Thyroid dysfunction was defi ned by current use of thyroid medications (thyroid hormone or antithyroid agents) or abnormal thyroxine level (T4 < 5.4 or T4 > 12.8 m g/dL). Body mass index (BMI) was calculated as weight (kg) divided by height square (m 2 ). Plasma homocysteine was measured by an automated fl uorescence polarization immunoassay method with the Abbott IMX system and the Abbott Axsym system (Abbott Diagnostics, Abbott Park, IL). Serum vitamin B 12 and red blood cell folate levels were measured using the Bio-Rad Laboratories folate/vitamin B 12 radioassay kit (Bio-Rad Laboratories, Hercules, CA). C-reactive protein (CRP) was quantifi ed by latex-enhanced nephelometry with a Dade Behring Nephelometer II Analyzer System (Dade Behring Diagnostics, Inc., Somerville, NJ). Plasma fi brinogen concentration was determined by the Clauss clotting method with an STA Compact Analyzer (Diagnostica Stago, Parsippany, NJ). Total cholesterol, serum thyroxine level, alanine aminotransferase, aspartate aminotransferase, and uric acid were measured with Hitachi analyzers (Roche Diagnostics, Indianapolis, IN). The participants were identifi ed to have recent exercise hobby if they did moderate or vigorous activities for at least 10 minutes in leisure time or muscle-strengthening activities over past 30 days. Current smoker was determined by plasma cotinine level of 14 ng/ mL or greater. Alcohol intake was determined by asking " In any 1 year, have you had at least 12 drinks of any type of alcohol beverage? " and was dichotomized. Study participants were classifi ed into two groups based on HAV immunoglobulin G (IgG) status: HAV IgG (+), seropositive HAV indicating past HAV infection, and HAV IgG ( − ), seronegative HAV indicating no past HAV infection. Baseline differences between the two groups were determined by Student ' s t test (for continuous variables) and chisquare test (for categorical variables). Right-skewed continuous variables including folate, vitamin B 12 , CRP, and homocysteine were log transformed before Student ' s t test was performed. With seronegative HAV participants as the reference group, differences of DSST score ( b coeffi cients) were obtained using linear regression. We further calculated the differences of DSST score ( b coeffi cients) while stratifi ed on each of the baseline characteristics to investigate whether the association between HAV seropositivity and DSST performance was similar across participant subgroups, as defi ned by a range of baseline characteristics. Effect modifi cations of baseline characteristics on the association between DSST performance and HAV seropositivity were examined by creating interaction terms, namely, Baseline Characteristics × HAV Status, in linear regression. A significant interaction effect was defi ned if signifi cance levels of interaction term were less than .05 in linear regression. In multivariable analysis, multiple linear regression was used to assess the relation of HAV seropositivity with DSST score. We used an extended-model approach for covariates adjustment: model 1 = demographic variables (age, sex, race, education, and annual family income); model 2 = model 1 + comorbidities (cardiovascular disease, hypertension, diabetes mellitus, lung disease, kidney disease, and thyroid dysfunc-tion); model 3 = model 2 + BMI + biomarkers (total cholesterol, folate, serum vitamin B 12 , CRP, homocysteine, fi brinogen, and uric acid); and model 4 = model 3 + health behavior (exercise hobby, smoking status, and alcohol consumption). We used the NHANES population weights (full-sample 4-year mobile examination center exam weight) for statistical analysis to generalize our results to the civilian household population of the United States. We also analyzed our data without the weights. Data analyses were performed using Statistics Package for Social Science 15.0 software (SPSS, Inc., Chicago, IL). Baseline characteristics of the study population as a whole ( n = 1,529, weighted mean age = 70.8 years) and by HAV IgG groups were summarized ( Table 1 ). The weighted , whereas values were expressed as median (IQR) in the right-skewed continuous variables. § Cardiovascular disease includes stroke, myocardial infarction, angina, coronary heart disease, or congestive heart failure, whereas lung disease includes asthma, chronic bronchitis, or emphysema. || Thyroid dysfunction includes abnormal thyroid function tests or currently using medication for thyroid dysfunction. ¶ Exercise hobby indicates participation in moderate activities, vigorous activities, or muscle-strengthening activities in leisure time. mean DSST score was lower in seropositive HAV group (44.4 vs 53.9, p < .001). More than half of the weighted study sample was non-Hispanic white (87.1%), and the weighted mean BMI was 28.2 kg/m 2 . Sixty-one percent of weighted study participants were HAV seropositive. Stratifi ed on a variety of baseline characteristics, the differences of DSST score ( b coeffi cients), comparing participants with seropositive HAV to those with seronegative HAV, were summarized ( Figure 1 ). Overall speaking, comparing participants with seropositive HAV to those with seronegative HAV, the unweighted b coeffi cient was − 11.3 (95% confi dence interval [CI] − 13.2 to − 9.3, p <.001) and the weighted b coeffi cient − 9.55 (95% CI − 9.57 to − 9.54, p <.001). The subgroup analysis demonstrated that the association between HAV seropositivity and DSST performance was consistent across the baseline characteristics. We did not fi nd signifi cant effect modifi cations of baseline characteristics on the association between DSST performance and HAV. In the multiple linear regression, participants with seropositive HAV tended to have lower DSST scores compared with those with seronegative HAV ( Table 2 ). The b coefficients for the association between DSST score and HAV IgG status were consistent across models. The adjusted b coeffi cients of DSST score in the full-adjusted model were − 2.01 (95% CI − 3.66 to − 0.37, p = 0.016) and − 2.48 (95% CI − 2.49 to − 2.46, p <0.001), unweighted and weighted, respectively. Among the U.S. noninstitutionalized older adults, previous HAV infection was associated with poorer cognitive function. This indicates that HAV infection may play a role in the decline of cognitive function or persons with lower cognitive performance may have increased risk for HAV infection. In our study, we have such strength as using a large national representative sample and comprehensive consideration of covariates. Several reports previously investigated the prevalence of HAV infection among people with intellectual disability. Williamson and colleagues ( 24 ) reported that the prevalence of HAV antibody in residents of institutions for intellectual disability was higher than that in the general population. Poovorawan and colleagues ( 25 ) demonstrated a high prevalence (92%) of HAV antibody among the young residents in the Institute for the Mentally Handicapped. These reports were in line with the negative association between HAV infection and cognitive function; however, they had weakness in terms of small sample size and external validity. Participants of the previous reports were confi ned to small groups of intellectual disabled patients. Moreover, no cognitive test was administered in any of the studies. To our knowledge, our study is the fi rst report to describe the association between HAV infection and cognitive function among community-dwelling older adults using a large group of geographically dispersed and ethnically diverse national population-based sample. Potential confounders affecting cognition were comprehensively considered. Our study shows that HAV is an independent inverse correlate of cognitive function. Possible explainable factors include lifestyle, environment, infl ammatory, and immunologic effects of HAV infection on brain damage and cooccurred complications of acute HAV infection. With regard to lifestyle and environmental factors, HAV-seropositive participants in our study tended to live in a poorer environment and pay less attention to health on the account of lower education level, lower annual family income, lower level of folate, and less exercise activity. We did not adjust for other factors associated with poor environment and unhealthy behavior, such as lead poisoning or illicit drug use. In aspects of comorbidities, we observed a higher prevalence of diabetes mellitus in HAV-seropositive participants, whereas no signifi cant differences in cardiovascular diseases and hypertension. Indeed, neither biologic fi ndings in the atheromatous plaque ( 26 ) nor longitudinal reports from the Heart Outcomes Prevention Evaluation studies ( 27 ) supported the notion that exposure to HAV might be associated with an excess risk for atherosclerosis or cardiovascular events. In contrast, because the majority of the diabetic participants in our study were affected with type 2 diabetes, a high prevalence of HAV seropositivity among the diabetic elders implies a possible interplay between HAV infection and type 2 diabetes. Wang and colleagues ( 28 ) recently reported a related fi nding that HCV infection was an independent predictor of type 2 diabetes. Although the mechanistic relationship between HAV infection and cognitive dysfunction is still unclear, direct demyelination and disruption in tryptophan metabolism were implicated in HCV-infected patients with neurological or psychological manifestations ( 29 -31 ) . Altogether, future research effort to provide a deeper understanding of the association between HAV infection and cognitive dysfunction is needed. The demonstrated results have several clinical implications. First, HAV infection may serve as a surrogate marker to early identify people at risk for lower cognitive performance. Timely preventive measures or intervention might ameliorate the deterioration process of cognitive decline in susceptible older adults. Second, hepatitis A is a preventable disease. Therefore, the possible neuropsychological infl uence of HAV vaccination in older adults needs to be further examined. Last, the successful experience of HCV antiviral treatment in the reduction of depressive symptoms Figure 1 . Effect of HAV seropositivity on cognition according to baseline characteristics. Notes : BMI, body mass index; CI, confi dence interval; CRP, C-reactive protein; DSST, Digit Symbol Substitution Test; HAV = hepatitis A virus; HAV IgG (+), seropositive for antihepatitis A virus immunoglobulin G; HAV IgG ( − ), seronegative for antihepatitis A virus immunoglobulin G; RBC, red blood cell; USD, U.S. dollar. *Seronegative HAV group was the reference group. † The diamond incorporates the point estimate, represented by the vertical dashed line, and the 95% CI of the overall effect. ‡ Elevated CRP means serum CRP level of >1 mg/dL, whereas hyperhomocysteinemia means serum homocysteine level of >11.9 m mol/ L. § Hyperfi brinogenemia means serum fi brinogen level of >400 mg/dL, whereas hyperuricemia means serum uric acid level of >7 mg/dL in men and >5.7 mg/dL in women. || Hypercholesterolemia means serum total cholesterol level of ≥ 200 mg/dL. ( 32 ) and improvement of cognitive function ( 33 ) suggested that search for the candidate treatment target for HAV infection is worth pursuing. Our study has the following limitations that deserve comments. First, the cross-sectional nature of data does not allow any causal inference. The relationship between cognitive function and HAV infection should be studied prospectively, and more studies are needed to clarify if direct effects of HAV on cognitive function exist. Second, we relied on selfreport to ascertain medical comorbidities and health-related behaviors. Such variables were potentially affected by depression, which was not examined in the NHANES participants older than 60 years. Third, some possible confounding factors such as hepatitis E virus (HEV) and human immunodefi ciency virus (HIV) infections were unknown in our study population. HEV is transmitted through the fecal -oral route and may have neurological or extrahepatic manifestations as HAV ( 2 , 34 ) . Homosexual men and drug users are at increased risk for HAV and HIV infections ( 35 ) . HIV infection is related to persistent and progressive changes in emotional and cognitive functions ( 36 ) . However, because data on HIV and HEV infections among the NHANES participants older than 60 years were not available, the possibility of coinfection cannot be excluded. Fourth, the DSST was the only neurocognitive test in the NHANES 1999 -2002, so we had no other neurocognitive tests for comparison. Finally, we had no information about the time when participants were infected with HAV, so we could not know when participants with seropositive HAV had lower cognitive function after infection. In conclusion, HAV seropositivity is associated with slower psychomotor speed among the U.S. communitydwelling elders after adjusting for multiple covariates. Our study is the fi rst report to demonstrate the relationship between HAV seropositivity and cognition in elderly adults. Further studies are needed to elucidate the role of HAV infection in the cognitive decline of the aging brain. Our study also provides a milieu to examine the possible protective effect of HAV vaccination. Financial support for data collection was provided by the NCHS, a part of the Centers for Disease Control and Prevention, Department of Health and Human Services. Notes: CI = confi dence interval; DSST = Digit Symbol Substitution Test. * Adjusted covariates: model 1 = demographic variables (age, sex, race, education, and annual family income); model 2 = model 1 + comorbidities (cardiovascular disease, hypertension, diabetes mellitus, lung disease, kidney disease, and thyroid dysfunction); model 3 = model 2 + body mass index + biomarkers (total cholesterol, folate, vitamin B 12 , C-reactive protein, homocysteine, fi brinogen, and uric acid); model 4 = model 3 + health behavior (exercise hobby, smoking status, and alcohol consumption). † Seronegative hepatitis A virus group was the reference group. Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach Extrahepatic manifestations of viral hepatitis Hepatitis A-induced diabetes mellitus, acute renal failure, and liver failure Hepatitis A virus infection presenting with seizures Hepatitis A: old and new Cognitive defi cits in patients with hepatic cirrhosis and in liver transplant recipients The neurology of liver failure Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy Subclinical impairment of brain function in chronic hepatitis C infection Neuropsychological function in Greek patients with chronic hepatitis C Acute disseminated encephalomyelitis associated with hepatitis A virus infection Hepatitis A post-viral encephalitis The possible role of hepatitis A virus in the pathogenesis of atherosclerosis Diabetes after infectious hepatitis: a follow-up study Type 2 diabetes mellitus and cognitive decline in two large cohorts of community-dwelling older adults Diabetes mellitus and dementia Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES) National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES) Manual for the Wechsler Adult Intelligence Scale-Revised Deterioration of frontal lobe function in normal aging: infl uences of fl uid intelligence versus perceptual speed Mental programming after frontal lobe lesions: results on digit symbol performance with self-selected goals A longitudinal study of hepatitis infection in an institution for the mentally retarded High prevalence of antibody against hepatitis A virus |in an institution for the mentally handicapped Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study Fulminant central nervous system demyelination associated with interferon-alpha therapy and hepatitis C virus infection Generation of a protective T-cell response following coronavirus infection of the central nervous system is not dependent on IL-12/23 signaling Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment . Dig Liver Dis Improved cognitive function as a consequence of hepatitis C virus treatment Seizure associated with acute hepatitis E Surveillance for acute viral hepatitis -United States Neurobiology of HIV, psychiatric and substance abuse comorbidity research: workshop report